Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Emory University
- Target Recruit Count
- 60
- Registration Number
- NCT03800693
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Mian XI
- Target Recruit Count
- 216
- Registration Number
- NCT03791905
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT03785873
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
- Conditions
- Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03784326
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
FOLFIRINOX for 2nd-line Treatment of BTC
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03778593
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 997
- Registration Number
- NCT03777657
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇫🇷CHU Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷Hôpital de la Timone, Marseille, France
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer
- Conditions
- Clinical Stage 0 Gastric Cancer AJCC V8Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastric Cancer AJCC V8Clinical Stage I Gastric Cancer AJCC V8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IVA Gastric Cancer AJCC V8Gastric AdenocarcinomaClinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03776487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- Procedure: Biopsy of BladderDrug: AtezolizumabDrug: CisplatinProcedure: Computed TomographyProcedure: CystoscopyDrug: GemcitabineDrug: FluorouracilProcedure: Magnetic Resonance ImagingDrug: MitomycinOther: Quality-of-Life AssessmentRadiation: Radiation TherapyOther: Survey AdministrationProcedure: Transurethral Resection of Bladder Tumor
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 475
- Registration Number
- NCT03775265
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Henry Ford Saint John Hospital - Macomb Medical, Macomb, Michigan, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03773367
- Locations
- 🇳🇴
Oslo University Hospital, Ullevål Hospital, Oslo, Norway
🇸🇪Karolinska University Hospital, Stockholm, Sweden
🇸🇪Lund University Hospital, Lund, Sweden
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 320
- Registration Number
- NCT03764553
- Locations
- 🇳🇱
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
🇳🇱Zuyderland Medisch Centrum, Geleen, Netherlands
🇳🇱Tergooi ziekenhuizen, Hilversum, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.